CareRx Performance degli utili passati
Criteri Il passato verificati 4/6
CareRx ha registrato una crescita degli utili a un tasso medio annuo di 56.7%, mentre il settore Consumer Retailing ha registrato utili in crescita a un tasso medio annuo di 0.5%. I ricavi sono stati in crescita a un tasso medio annuo di 9%. Il ritorno sul capitale proprio di CareRx è 24.5% e ha margini netti di 7.2%.
Informazioni chiave
56.75%
Tasso di crescita degli utili
64.20%
Tasso di crescita dell'EPS
| Consumer Retailing Crescita del settore | 10.26% |
| Tasso di crescita dei ricavi | 8.95% |
| Rendimento del capitale proprio | 24.52% |
| Margine netto | 7.23% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • Jun 16
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.
Aggiornamento della narrazione • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.Aggiornamento della narrazione • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Aggiornamento della narrazione • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Aggiornamento della narrazione • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).Aggiornamento della narrazione • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Aggiornamento della narrazione • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Aggiornamento della narrazione • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Aggiornamento della narrazione • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Aggiornamento della narrazione • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Aggiornamento della narrazione • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Aggiornamento della narrazione • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Aggiornamento della narrazione • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Aggiornamento della narrazione • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Articolo di analisi • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nuova narrazione • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Articolo di analisi • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Articolo di analisi • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Articolo di analisi • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Articolo di analisi • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Articolo di analisi • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come CareRx guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 375 | 27 | 100 | 0 |
| 31 Dec 25 | 370 | 26 | 100 | 0 |
| 30 Sep 25 | 366 | 0 | 100 | 0 |
| 30 Jun 25 | 366 | -2 | 100 | 0 |
| 31 Mar 25 | 367 | -4 | 101 | 0 |
| 31 Dec 24 | 367 | -5 | 101 | 0 |
| 30 Sep 24 | 366 | -6 | 98 | 0 |
| 30 Jun 24 | 367 | -7 | 99 | 0 |
| 31 Mar 24 | 369 | -4 | 98 | 0 |
| 31 Dec 23 | 371 | -5 | 98 | 0 |
| 30 Sep 23 | 374 | -6 | 100 | 0 |
| 30 Jun 23 | 378 | -7 | 100 | 0 |
| 31 Mar 23 | 380 | -34 | 101 | 0 |
| 31 Dec 22 | 382 | -34 | 103 | 0 |
| 30 Sep 22 | 384 | -34 | 101 | 0 |
| 30 Jun 22 | 358 | -36 | 94 | 0 |
| 31 Mar 22 | 311 | -20 | 83 | 0 |
| 31 Dec 21 | 263 | -23 | 71 | 0 |
| 30 Sep 21 | 212 | -21 | 61 | 0 |
| 30 Jun 21 | 187 | -24 | 55 | 0 |
| 31 Mar 21 | 177 | -29 | 52 | 0 |
| 31 Dec 20 | 162 | -18 | 48 | 0 |
| 30 Sep 20 | 148 | -50 | 44 | 0 |
| 30 Jun 20 | 134 | -47 | 42 | 0 |
| 31 Mar 20 | 126 | -34 | 41 | 0 |
| 31 Dec 19 | 125 | -46 | 41 | 0 |
| 30 Sep 19 | 122 | -19 | 42 | 0 |
| 30 Jun 19 | 119 | -20 | 41 | 0 |
| 31 Mar 19 | 117 | -39 | 41 | 0 |
| 31 Dec 18 | 119 | -35 | 41 | 0 |
| 30 Sep 18 | 85 | -27 | 27 | 0 |
| 30 Jun 18 | 97 | -23 | 31 | 0 |
| 31 Mar 18 | 110 | -3 | 34 | 0 |
| 31 Dec 17 | 122 | -4 | 38 | 0 |
| 30 Sep 17 | 168 | -6 | 55 | 0 |
| 30 Jun 17 | 170 | -3 | 56 | 0 |
| 31 Mar 17 | 170 | -13 | 58 | 0 |
| 31 Dec 16 | 167 | -18 | 59 | 0 |
| 30 Sep 16 | 166 | -21 | 64 | 0 |
| 30 Jun 16 | 166 | -34 | 66 | 0 |
| 31 Mar 16 | 164 | -30 | 67 | 0 |
| 31 Dec 15 | 161 | -35 | 67 | 0 |
| 30 Sep 15 | 27 | -47 | 13 | 0 |
Guadagni di qualità: CRRX ha guadagni di alta qualità.
Margine di profitto in crescita: CRRX è diventata redditizia in passato.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CRRX è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 56.7% all'anno.
Accelerare la crescita: CRRX è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.
Guadagni vs Settore: CRRX è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Consumer Retailing ( 15.6% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 24.5% ) di CRRX è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/08 23:16 |
| Prezzo dell'azione a fine giornata | 2026/07/08 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
CareRx Corporation è coperta da 11 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |